Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 18;18(3):sfaf009.
doi: 10.1093/ckj/sfaf009. eCollection 2025 Mar.

CD163 detection in immune check-point inhibitors-related acute interstitial nephritis

Affiliations

CD163 detection in immune check-point inhibitors-related acute interstitial nephritis

Thomas Perier et al. Clin Kidney J. .

Abstract

Background: Acute interstitial nephritis (AIN) is the most common renal immune-related adverse event after immune check-point inhibitors (ICI). We hypothesized that alternatively activated macrophages (CD163-M) could be involved in ICI-AIN and wished to evaluate the use of their soluble urinary form (us)CD163 as a non-invasive diagnostic marker.

Methods: CD163-M infiltrates were evaluated by both immune-histochemistry and multiplex immunofluorescence and imaging. usCD163 was detected with ELLA technology and evaluated together with urinary creatinine to be expressed as a ratio to creatinuria in ng/mmol. Clinical data were collected to perform correlations with renal function assessed by estimated glomerular filtration rate (eGFR).

Results: A retrospective cohort of 63 ICI-exposed patients with tubular acute kidney injury profile requiring a biopsy were selected. AIN patients (n = 44) were compared to acute tubular necrosis (ATN) patients (n = 19). CD163-M staining was detectable in all ICI-AIN patients, which was significantly higher than in ATN patients (18.4% vs 3.6% of area, P = .005). CD163-M staining was restricted to the interstitial compartment. CD163-M infiltrate inversely correlated with initial eGFR (r = -0.6, P = .003), and was positively correlated with delta eGFR, reflecting a renal improvement outcome (r = 0.48; P = .02). usCD163 was well detected in urines of patients, but did not allow us to distinguish ATN from AIN patients at diagnosis. No correlation was observed, neither between usCD163 and CD163-M staining nor with renal response after 3 months of glucocorticoid tapering.

Conclusion: CD163-M are detected in ICI-AIN and correlate both with severity at diagnosis and better prognosis at 3 months. CD163-M may help us to distinguish AIN from ATN but, it does not allow us to assess ICI imputability. Although detected in urine, usCD163 is clearly not a surrogate biomarker for AIN diagnosis.

Keywords: CD163; alternatively activated macrophage; immune check-point inhibitors acute interstitial nephritis ICI-AIN; urinary soluble usCD163.

PubMed Disclaimer

Conflict of interest statement

Dr Belliere Julie : Employer: Centre hospitalier universitaire de Toulouse; Symposia: Astellas, Sandoz, CSL-Vifor, Sanofi, Congrès Colloques Convention, AstraZeneca.

Figures

Figure 1:
Figure 1:
Flowchart of the study.
Figure 2:
Figure 2:
CD163-(M) macrophages in ICI-AIN kidney biopsies. CD163 immunohistochemistry detection in kidney biopsies. (a) A representative example is depicted for both ATN and AIN patients, in the left and right panels, respectively. (b) CD163 staining, expressed in percentage of area in each group (n = 8 for ATN and n = 26 for ICI-AIN) P = .0005. (c) CD163 infiltration was associated with severity of ICI-AIN at diagnosis (a high CD163-M staining was found to be associated with a low eGFR, n = 25, **P = .003). (d) CD163-M infiltration at ICI-AIN diagnosis was associated with a favourable delta eGFR at 3 months (delta = eGFR at 3 months; eGFR at AIN diagnosis), n = 22, *P = .02.
Figure 3:
Figure 3:
usCD163 detection in patients with ICI-AIN. (a) Albuminuria/urinary creatinine (A/C) ratio, expressed in mg/g. Threshold at 300 mg/g is indicated with horizontal line. (b) Proteinuria/urinary creatinine (P/C) ratio, expressed in mg/g. (c) usCD163 correlation with CD163 staining. (d, e, f) usCD163 correlation with degree or fibrosis and severity of AKI (initial eGFR).
Figure 4:
Figure 4:
UsCD163 kinetic across AIN evolution in patients with available samples and renal response after 3 months (M3) of glucocorticoids (n = 19). (a) Individual values are plotted at diagnosis and M3. The proportion of patients with stable, increase, or decrease values is represented in a pie chart. (b) An illustrative example is depicted for a patient with longitudinal usCD163 monitoring and complete renal response. (c) UsCD163 values are depicted at diagnosis, in patients with PR compared to CR. (d) Patients in PR only (n = 8). Individual values are plotted at diagnosis and M3. Proportion of patients with stable, increase, or decrease values is represented in pie chart. (e) Patients in CR only (n = 11). Individual values are plotted at diagnosis and M3. The proportion of patients with stable, increase, or decrease values is represented in a pie chart.

References

    1. Singh S, Long JP, Tchakarov A et al. Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis. JCI Insight 2022;0–39. 10.1172/jci.insight.165108 - DOI - PubMed
    1. Pfenning MB, Schmitz J, Scheffner I et al. High macrophage densities in native kidney biopsies correlate with renal dysfunction and promote ESRD. Kidney Int Rep 2023;8:341–56. 10.1016/j.ekir.2022.11.015 - DOI - PMC - PubMed
    1. Tabei A, Watanabe M, Ikeuchi H et al. The analysis of renal infiltrating cells in acute tubulointerstitial nephritis induced by anti-PD-1 antibodies: a case report and review of the literature. Intern Med 2018;57:3135–9. 10.2169/internalmedicine.0444-17 - DOI - PMC - PubMed
    1. Tominaga K, Takeuchi K, Takakuma S et al. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report. BMC Nephrol 2023;24:48. 10.1186/s12882-023-03091-8 - DOI - PMC - PubMed
    1. Okawa S, Fujiwara K, Shimonishi A et al. Rapidly progressive acute kidney injury associated with Nivolumab treatment. Case Rep Oncol 2020;13:85–90. 10.1159/000505235 - DOI - PMC - PubMed